Skip to main content
OpenTrials
Completed

NCT Number: NCT05646004

621 Real World Study

This study is evaluating the clinical safety and effectiveness of 621, after cataract surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hainan Boao Lecheng Aier Eye Hospital

Qionghai, Hainan, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Age ≥ 18 years old;
  • Patient with clinically significant cataract with planned phacoemulsification cataract extraction and implantation of IOL into the capsular bag;
  • Preoperative corneal astigmatism ≤ 1.00D;
  • Patient is willing and capable of providing informed consent;
  • Patient is willing and capable of complying with visits and procedures as defined by this protocol.

Exclusion:

  • Preoperative best corrected visual acuity > 4.7 or ≤ 0.3 logMAR;
  • Corneal endothelial cell count less than 2000 cell/mm2;
  • Age under 18 years old;
  • Pregnant and lactating women;
  • Patients who attend other drug or medical device study;
  • Ocular disorder that could potentially cause a clinically significant future visual acuity loss;
  • Anterior segment pathology (e.g. chronic uveitis, iritis, aniridia, rubeosis iridis, anterior membrane dystrophies, poor pupil dilation, etc.)
  • Abnormal corneal finding (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically significant corneal membrane dystrophies);
  • Any condition in the study eye that could affect IOL stability (e.g. pseudo-exfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc;
  • Any acute infection (acute ocular disease, external/internal infection, systemic infection);
  • History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy, amblyopia, strabismus, microphthalmia, aniridia, epiretinal membrane etc.) in the study eye that could alter or limit final postoperative visual prognosis;
  • Any previous intraocular and corneal surgery ;
  • Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment;
  • Current systemic or ocular pharmacotherapy that effects patients' vision;
  • Current pathology or condition that could be a risk for the patient according to the investigator opinion;
  • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the clinical investigation;
  • Patients whose freedom is impaired by administrative or legal order.

Treatment and study plan

Cataract surgery

Device

Implantation of 621 lens

Primary outcomes

  1. Percentage of Participants With a Monocular CDVA ≤0.3 logMAR at 6 Months Postoperatively

    Time frame: 6 months

    Percentage of Participants with a Monocular CDVA ≤0.3 logMAR at 6 Months Postoperatively,

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

An Open Single-arm Clinical Investigation to Evaluate the Clinical Safety and Effectiveness of 621

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Dec 12, 2022
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.